On 24 January 2013, orphan designation (EU/3/12/1096) was granted by the European Commission to Serodapharm GmbH, Germany, for terguride for the treatment of systemic sclerosis.

The sponsorship was transferred to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, in August 2016.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2021 on request of the Sponsor.

Key facts

Active substance
Intented use
Treatment of systemic sclerosis
Date of designation
Orphan designation status
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
D-22880 Wedel
Tel. + 49 4103 8006 0
Fax + 49 4103 8006 100

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating